Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Haanen

Showing results (71-80 of 161) with videos related to

Pageof 17
Sort By:
Leukemia|June 1, 1993
Effect of doxorubicin, daunorubicin, and idarubicin on the growth rate of human leukemia cells (K562) studied with image analysisH Minderman, H K Slocum, M Malmberg, et al.
The Netherlands Journal of Medicine|February 1, 1990
Continuous intravenous administration of daunorubicin and cytarabine for remission induction of poor risk acute myelogenous leukaemias and myelodysplastic syndromesB M Bär, T de Witte, B E de Pauw, et al.
Scandinavian Journal of Haematology|October 1, 1985
Intermittent melphalan in the treatment of essential thrombocytosis with haemorrhage or thrombosisB E de Pauw, A N van Bergen, C Haanen, et al.
Blut|May 1, 1988
Recombinant human interferon-alpha induced cytoreduction in chronic myelogenous leukemia. Results of a multicenter studyM Werter, R de Witte, J Janssen, et al.
Leukemia Research|January 1, 1991
Immunotherapy with monoclonal anti-idiotypic antibodies: tumour reduction and lymphokine productionW Allebes, R Knops, M Herold, et al.
Acta Haematologica|January 1, 1983
DNA-flow cytometry of blood and bone marrow in chronic myelogenous leukemiaR S Holdrinet, A Pennings, J van Egmond, et al.
Cytometry|September 1, 1981
Simplified method for DNA and protein staining of human hematopoietic cell samplesH A Crissman, J Van Egmond, R S Holdrinet, et al.
Cancer Chemotherapy and Pharmacology|June 10, 1998
Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic modelH J Guchelaar, I Vermes, R P Koopmans, et al.
Blut|April 1, 1981
Spontaneous lymphocyte transformation in relation to the number of circulating lymphocytes in Hodgkin's diseaseP H de Mulder, B E de Pauw, D J Wagener, et al.
Seminars in Oncology|June 1, 1987
Influence of dose and duration of exposure on the cytotoxic effect of cytarabine toward human hematopoietic clonogenic cellsP Muus, C Haanen, R Raijmakers, et al.
Pageof 17

Showing results (71-80 of 161) with videos related to

Sort By:
Pageof 17
Leukemia|June 1, 1993
Effect of doxorubicin, daunorubicin, and idarubicin on the growth rate of human leukemia cells (K562) studied with image analysisH Minderman, H K Slocum, M Malmberg, et al.
The Netherlands Journal of Medicine|February 1, 1990
Continuous intravenous administration of daunorubicin and cytarabine for remission induction of poor risk acute myelogenous leukaemias and myelodysplastic syndromesB M Bär, T de Witte, B E de Pauw, et al.
Scandinavian Journal of Haematology|October 1, 1985
Intermittent melphalan in the treatment of essential thrombocytosis with haemorrhage or thrombosisB E de Pauw, A N van Bergen, C Haanen, et al.
Blut|May 1, 1988
Recombinant human interferon-alpha induced cytoreduction in chronic myelogenous leukemia. Results of a multicenter studyM Werter, R de Witte, J Janssen, et al.
Leukemia Research|January 1, 1991
Immunotherapy with monoclonal anti-idiotypic antibodies: tumour reduction and lymphokine productionW Allebes, R Knops, M Herold, et al.
Acta Haematologica|January 1, 1983
DNA-flow cytometry of blood and bone marrow in chronic myelogenous leukemiaR S Holdrinet, A Pennings, J van Egmond, et al.
Cytometry|September 1, 1981
Simplified method for DNA and protein staining of human hematopoietic cell samplesH A Crissman, J Van Egmond, R S Holdrinet, et al.
Cancer Chemotherapy and Pharmacology|June 10, 1998
Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic modelH J Guchelaar, I Vermes, R P Koopmans, et al.
Blut|April 1, 1981
Spontaneous lymphocyte transformation in relation to the number of circulating lymphocytes in Hodgkin's diseaseP H de Mulder, B E de Pauw, D J Wagener, et al.
Seminars in Oncology|June 1, 1987
Influence of dose and duration of exposure on the cytotoxic effect of cytarabine toward human hematopoietic clonogenic cellsP Muus, C Haanen, R Raijmakers, et al.
Pageof 17